1. A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder. (1st February 2017) Authors: Thase, Michael; Asami, Yuko; Wajsbrot, Dalia; Dorries, Kathleen; Boucher, Matthieu; Pappadopulos, Elizabeth Journal: Current medical research and opinion Issue: Volume 33:Number 2(2017) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. (May 2016) Authors: Carrasco, José L.; Kornstein, Susan G.; McIntyre, Roger S.; Fayyad, Rana; Prieto, Rita; Salas, Maribel; Mackell, Joan; Boucher, Matthieu Journal: International clinical psychopharmacology Issue: Volume 31:Number 3(2016:May) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine. (15th November 2017) Authors: Soares, Claudio N.; Zhang, Min; Boucher, Matthieu Journal: CNS spectrums Issue: Volume 24:Number 3(2019) Page Start: 322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis. (October 2020) Authors: Kato, Masaki; Asami, Yuko; Wajsbrot, Dalia B.; Wang, Xuemei; Boucher, Matthieu; Prieto, Rita; Pappadopulos, Elizabeth Journal: Journal of psychiatric research Issue: Volume 129(2020) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Desvenlafaxine for the treatment of major depressive disorder. (July 2014) Authors: Kornstein, Susan G; McIntyre, Roger S; Thase, Michael E; Boucher, Matthieu Journal: Expert opinion on pharmacotherapy Issue: Volume 15:Number 10(2014) Page Start: 1449 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of β-Adrenergic Receptors to Phosphoinositide 3-Kinase. (13th January 2009) Authors: Simard, Julie; Boucher, Matthieu; Massé, Rachel; Hébert, Terence E.; Rousseau, Guy Other Names: Brennwald Patrick J. Academic Editor. Journal: International journal of cell biology Issue: Volume 2009(2009) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of β-Adrenergic Receptors to Phosphoinositide 3-Kinase. (13th January 2009) Authors: Simard, Julie; Boucher, Matthieu; Massé, Rachel; Hébert, Terence E.; Rousseau, Guy Other Names: Brennwald Patrick J. Academic Editor. Journal: International journal of cell biology Issue: Volume 2009(2009) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis. (September 2017) Authors: Lam, Raymond W; Wajsbrot, Dalia B; Meier, Ellen; Pappadopulos, Elizabeth; Mackell, Joan A; Boucher, Matthieu Journal: Journal of psychopharmacology Issue: Volume 31:Number 9(2017) Page Start: 1204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder. (3rd March 2016) Authors: McIntyre, Roger S.; Fayyad, Rana; Mackell, Joan A.; Boucher, Matthieu Journal: Current medical research and opinion Issue: Volume 32:Number 3(2016:Mar.) Page Start: 587 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder. (November 2015) Authors: Clayton, Anita H.; Hwang, Eunhee; Kornstein, Susan G.; Tourian, Karen A.; Cheng, Ru-fong; Abraham, Lucy; Mele, Linda; Boucher, Matthieu Journal: International clinical psychopharmacology Issue: Volume 30:Number 6(2015:Nov.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗